The cytoskeleton in neurodegenerative diseases

Journal of Pathology

Volumn 204, Issue 4, 2004, Pages 438-449

  Cairns, Nigel J ^a   Lee, Virginia M Y ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cytoskeleton; Mutation; Neurodegenerative disease; Neuronal intermediate filament; Peripheral neuropathy; Tau

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYTOSKELETON PROTEIN; INTERMEDIATE FILAMENT PROTEIN; TAU PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; CELL INCLUSION; CHROMOSOME 17; CORTICOBASAL DEGENERATION; CYTOSKELETON; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC RISK; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERMEDIATE FILAMENT; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; RNA SPLICING; TRANSGENIC ANIMAL;

ANIMALS; CYTOSKELETAL PROTEINS; CYTOSKELETON; DISEASE MODELS, ANIMAL; HUMANS; INTERMEDIATE FILAMENTS; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS; PERIPHERAL NERVOUS SYSTEM DISEASES; TAU PROTEINS;

EID: 7944236911     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1650     Document Type: Review

References (126)

1. Lee K, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci 1996; 19: 187-217.
2. Lee VM-Y, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159.
3. Goedert M, Spillantini MG, Serpell LC, et al. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc London Ser B Biol Sci 2001; 356: 213-227.
4. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 55-56.
5. Al-Chalabi A, Miller CCJ. Neurofilaments and neurological disease. Bioessays 2003; 25: 346-365.
6. Lariviere RC, Julien JP. Functions of intermediate filaments in neuronal development and disease. J Neurobiol 2004; 58: 131-148.
7. Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126: 590-597.
8. De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001; 49: 245-249.
9. Yoshihara T, Yamamoto M, Hattori N, et al. Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. J Peripher Nerv Syst 2002; 7 221-224.
10. Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou K. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 2002; 4: 93-96.
11. Fabrizi GM, Cavallaro T, Angiari C, et al. Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology 2004; 62: 1429-1431.
12. Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67: 37-46.
13. Zuchner S, Vorgerd M, Sindern E, Schroder JM. The novel neurofilament light (NEFL) mutation Glu397Lys is associated with a clinically and morphologically heterogeneous type of Charcot-Marie-Tooth neuropathy. Neuromuscul Disord 2004; 14: 147-157.
14. Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci Lett 2002; 322: 57-61.
15. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-1761.
16. Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-164.
17. Tomkins J, Usher P, Slade JY, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998; 9: 3967-3970.
18. Hayashi S, Toyoshima Y, Hasegawa M, et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol 2002; 51: 525-530.
19. Poorkaj P, Muma NA, Zhukareva V, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 2002; 52: 511-516.
20. Pickering-Brown S, Baker M, Yen SH, et al. Pick's disease is associated with mutations in the tau gene. Ann Neurol 2000; 48: 859-867.
21. Rizzini C, Goedert M, Hodges JR, et al. Tau gene mutation K257T causes a tauopathy similar to Pick's disease. J Neuropathol Exp Neurol 2000; 59: 990-1001.
22. Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging 2001; 22: 89-107.
23. Kobayashi T, Ota S, Tanaka K, et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol 2003; 53: 133-137.
24. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-705.
25. Rizzu P, Van Swieten JC, Joosse M, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in The Netherlands. Am J Hum Genet 1999; 64: 414-421.
26. Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 1998; 95: 13 103-13 107.
27. D'Souza I, Poorkaj P, Hong M, et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A 1999; 96 5598-5603.
28. Spillantini MG, Yoshida H, Rizzini C, et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000: 48: 939-943.
29. Iseki E, Matsumura T, Marui W, et al. Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in glial cells. Acta Neuropathol 2001; 102: 285-292.
30. Pastor P, Pastor E, Carnero C, et al. Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene. Ann Neurol 2001; 49: 263-267.
31. Bugiani O, Murrell JR, Giaccone G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999; 58: 667-677.
32. Sperfeld AD, Collatz MB, Baier H, et al. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999; 46: 708-715.
33. Hasegawa M, Smith MJ, Iijima M, Tabira T, Goedert M. FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Lett 1999; 443: 93-96.
34. Iijima M, Tabira T, Poorkaj P, et al. A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport 1999; 10: 497-501.
35. Stanford PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 2000; 123: 880-893.
36. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 1998; 8: 387-402.
37. Miyamoto K, Kowalska A, Hasegawa M, et al. Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10 + 11-splice site in the tau gene. Ann Neurol 2001; 50 117-120.
38. Yasuda M, Takamatsu J, D'Souza I, et al. A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Ann Neurol 2000; 47: 422-429.
39. Lantos PL, Cairns NJ, Khan MN, et al. Neuropathologic variation in frontotemporal dementia due to the intronic tau 10 (+16) mutation. Neurology 2002; 58: 1169-1175.
40. van Herpen E, Rosso SM, Serverijnen LA, et al. Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. Ann Neurol 2003; 54: 573-581.
41. Rosso SM, van Herpen E, Deelen W, et al. A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Ann Neurol 2002; 51: 373-376.
42. Pickering-Brown SM, Baker M, Nonaka T, et al. Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. Brain 2004; 127: 1415-1426.
43. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43: 815-825.
44. Lippa CF, Zhukareva V, Kawarai T, et al. Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Ann Neurol 2000; 48: 850-858.
45. Nicholl DJ, Greenstone MA, Clarke CE, et al. An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol 2003; 54: 682-686.
46. Neumann M, Schulz-Schaeffer W, Crowther RA, et al. Pick's disease associated with the novel tau gene mutation K369I. Ann Neurol 2001; 50: 503-513.
47. Murrell JR, Spillantini MG, Zolo P, et al. Tau gene mutation G389R causes a tanopathy with abundant pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol 1999; 58: 1207-1226.
48. Ching GY, Liem RKH. Structure of the gene for the neuronal intermediate filament protein α-internexin and functional analysis of its promoter. J Biol Chem 1991; 266: 19459-19468.
49. Schmidt ML, Carden MJ, Lee VM-Y, Trojanowski JQ. Phosphate dependent and independent neurofilament epitopes in the axonal swellings of patients with motor neuron disease and controls. Lab Invest 1987; 56: 282-294.
50. Ching GY, Liem RKH. Roles of head and tail domains in α-internexin's self-assembly and coassembly with the neurofilament triplet proteins. J Cell Science 1998; 111: 321-333.
51. Lee VM-Y, Carden MJ, Schlaepfer WW, Trojanowski JQ. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci 1987; 7: 3478-3488.
52. Carden MJ, Trojanowski JQ, Schlaepfer WW, Lee VM-Y. Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci 1987; 7: 3499-3504.
53. Hill WD, Lee VM-Y, Hurtig HI, Murray JM, Trojanowski JQ. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy body. J Comp Neurol 1991; 309: 150-160.
54. Schmidt ML, Murray J, Lee VM-Y, Hill WD, Wertkin A, Trojanowski JQ. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991; 139 53-65.
55. Manetto V, Sternberger NH, Perry G, Sternberger LA, Gambetti P. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988; 47: 642-653.
56. Leigh PN, Dodson A, Swash M, Brion JP, Anderton BH. Cytoskeletal abnormalities in motor neuron disease: an immunohistochemical study. Brain 1989; 112: 521-535.
57. Goldstein E, Sternberger NM, Sternberger LA. Phosphorylation protects neurofilaments against proteolysis. J Neuroimmunol 1987; 14: 149-160.
58. Fliegner KH, Kaplan MP, Wood TL, Pintar JE, Liem RK. Expression of the gene for the neuronal intermediate filament protein α-internexin coincides with the onset of neuronal differentiation in the developing rat nervous system. J Comp Neurol 1994; 342: 161-173.
59. Cairns NJ, Zhukareva V, Uryu K, et al. α-Internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 2004; 164: 2153-2161.
60. Cairns NJ, Uryu K, Bigio E, et al. α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 2004; 108: 213-223.
61. Josephs KA, Holton JL, Rossor MN, et al. Neurofilament inclusion body disease: a new proteinopathy? Brain 2003; 126: 2291-2303.
62. He CZ, Hays AP. Expression of peripherin in ubiquinated inclusions of amyotrophic lateral sclerosis. J Neurol Sci 2004; 217: 47-54.
63. Strong MJ, Strong WL, Jaffe H, Traggert B, Sopper MM, Pant HC. Phosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis. J Neurochem 2001; 76: 1315-1325.
64. Perez-Olle R, Leung CL, Liem RK. Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci 2002; 115: 4937-4946.
65. Galvin JE, Nakamura M, McIntosh TK, et al. Neurofilament-rich intraneuronal inclusions exacerbate neurodegenerative sequelae of brain trauma in NFH/LacZ transgenic mice. Exp Neurol 2000; 165: 77-89.
66. Ching GY, Chien C-L, Flores R, Liem RKH. Overexpression of α-internexin causes abnormal neurofilamentous accumulations and motor coordination deficits in transgenic mice. J Neurosci 1999; 19 2974-2986.
67. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994; 13 975-988.
68. Canete-Soler R, Silberg DG, Gershon MD, Schlaepfer WW. Mutation in neurofilament transgene implicates RNA processing in the pathogenesis of neurodegenerative disease. J Neurosci 1999; 19 1273-1283.
69. Beaulieu JM, Julien JP. Peripherin-mediated death of motor neurons rescued by overexpression of neurofilament NF-H proteins. J Neurochem 2003; 85: 248-256.
70. Robertson J, Doroudchi MM, Nguyen MD, et al. A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol 2003; 160: 939-949.
71. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41: 706-715.
72. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998; 95: 7737-7741.
73. Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 1977; 116: 207-225.
74. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985; 101 1371-1378.
75. Shin RW, Iwaki T, Kitamoto T, Tateishi J. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab Invest 1991; 64: 693-702.
76. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A 1995; 92: 10369-10373.
77. Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci U S A 1992; 89: 4378-4381.
78. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 1986; 387: 271-280.
79. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 1988; 85: 4051-4055.
80. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry 1992; 31: 10626-10633.
81. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519-526.
82. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8: 393-399.
83. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 1990; 9: 4225-4230.
84. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914-1917.
85. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975; 72: 1858-1862.
86. Himmler A, Drechsel D, Kirschner MW, Martin DW Jr. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 1989; 9: 1381-1388.
87. Lee G, Neve RL, Kosik KS. The microtubule binding domain of tau protein. Neuron 1989; 2: 1615-1624.
88. Butner KA, Kirschner MW. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 1991; 115: 717-730.
89. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992; 3: 1141-1154.
90. Yoshida H, Ihara Y. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem 1993; 61: 1183-1186.
91. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-1099.
92. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993; 11: 153-163.
93. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577-591.
94. Buée L, Bussière T, Buée-Seherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33 1-36.
95. Hong M, Trojanowski JQ, Lee VM-Y. Tau-based neurofibrillary lesions. In Neurodegenerative Dementias, Clark CM, Trojanowski JQ (eds). McGraw-Hill: New York, 2000; 161-175.
96. Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett 1996; 384: 25-30.
97. Hoffmann R, Lee VM-Y, Leight S, Varga I, Otvos L Jr. Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 1997; 36 8114-8124.
98. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. Sequential phosphorylation of tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 1998; 252: 542-552.
99. Yasuda M, Kawamata T, Komure O, et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 1999; 53: 864-868.
100. Delisle MB, Murrell JR, Richardson R, et al. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol 1999; 98: 62-77.
101. Varani L, Hasegawa M, Spillantini MG, et al. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci U S A 1999; 96: 8229-8234.
102. Grover A, Houlden H, Baker M, et al. 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem 1999; 274: 15 134-15 143.
103. D'Souza I, Schellenberg D. Determinants of 4 repeat tau expression: coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. J Biol Chem 2000; 275: 17 700-17 709.
104. Gao QS, Memmott J, Lafyatis R, Stamm S, Screaton G, Andreadis A. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J Neurochem 2000; 74: 490-500.
105. Grover A, DeTure M, Yen SH, Hutton M. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci Lett 2002; 323: 33-36.
106. Hulette CM, Pericak-Vance MA, Roses AD, et al. Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke family 1684. J Neuropathol Exp Neurol 1999; 58: 859-866.
107. Goedert M, Spillantini MG, Crowther RA, et al. Tau gene mutation in familial progressive subcortical gliosis. Nature Med 1999; 5: 454-457.
108. Arima K, Kowalska A, Hasegawa M, et al. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000; 54: 1787-1795.
109. Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 1994; 124: 769-782.
110. Goode BL, Denis PE, Panda D, et al. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol Biol Cell 1997; 8: 353-365.
111. Hasegawa M. Smith MJ, Goedert M. Tau proteins with FTDP17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998; 437: 207-210.
112. Barghorn S, Zheng-Fischhofer Q, Ackmann M, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 2000; 39: 11714-11721.
113. Rizzu P, Joosse M, Ravid R, et al. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Hum Mol Genet 2000; 9: 3075-3082.
114. Miyasaka T, Morishima-Kawashima M, Ravid R, et al. Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. J Neuropathol Exp Neurol 2001; 60: 872-884.
115. Arrasate M, Perez M, Armas-Portela R, Avila J. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett 1999; 446: 199-202.
116. Nacharaju P, Lewis J, Easson C, et al. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 1999; 447: 195-199.
117. Goedert M, Jakes R, Crowther RA. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 1999; 450: 306-311.
118. Gamblin TC, King ME, Dawson H, et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 2000; 39: 6136-6144.
119. Goedert M, Satumtira S, Jakes R, et al. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J Neurochem 2000; 75: 2155-2162.
120. Götz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276: 529-534.
121. Götz J. Tau and transgenic animal models. Brain Res Rev 2001; 35: 266-286.
122. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet 2000; 25: 402-405.
123. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24 751-762.
124. Wittmann CW, Wszolek MF, Shulman JM, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293: 711-714.
125. Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002; 34: 509-519.
126. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 2003; 100: 9980-9985.